What semaglutide is
Semaglutide is a medication that copies the action of GLP-1, a hormone your body releases after you eat. According to the FDA-approved prescribing information for Wegovy®, semaglutide is a GLP-1 analogue with 94 percent sequence homology to human GLP-1, and it works by binding to and activating the GLP-1 receptor. The same label describes GLP-1 as a physiological regulator of appetite and caloric intake, and notes that the GLP-1 receptor is present in several areas of the brain involved in appetite regulation.
In plain terms, semaglutide acts on the signals that tell you that you have eaten enough. People taking it usually report feeling full sooner and staying full longer, which makes it easier to eat less without a constant effort of will. The drug is taken as an injection under the skin once a week.
Semaglutide is the active ingredient in two FDA-approved products from the same manufacturer. Wegovy® is approved for weight reduction in adults with obesity, and in adults with overweight who have at least one weight-related condition, among other indications listed on its label. Ozempic® is approved, per its own prescribing information, to improve blood sugar control in adults with type 2 diabetes and to reduce certain cardiovascular and kidney risks in that population. It is not approved for weight management on its own. Brand names are trademarks of their respective owners, and Bodi Envi is not affiliated with them.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What “compounded” means
Compounding is an established part of pharmacy practice, and it has a specific legal meaning. The FDA’s human drug compounding page defines it as the practice in which a licensed pharmacist, a licensed physician, or in the case of an outsourcing facility a person under the supervision of a licensed pharmacist, combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.
Personalized Compounded semaglutide, then, is semaglutide prepared by a compounding pharmacy for one patient, based on that patient’s prescription, rather than a finished product taken off a manufacturer’s line. It typically comes as a vial of solution that you draw up with a syringe, rather than a pre-filled pen, though the exact presentation depends on the pharmacy.
The most important thing to understand is what compounding does not mean. The FDA states plainly that compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed. That is not a footnote. It is the central difference between a compounded medication and a branded one, and every page on this site that discusses compounded treatment says so.
Who prepares personalized compounded semaglutide and under what rules
Two kinds of facilities are allowed to compound drugs in the United States, and they are regulated differently. The FDA’s compounding questions and answers page explains that state-licensed pharmacies that are not registered as outsourcing facilities, often called 503A pharmacies after the section of the law that covers them, are overseen day to day by state boards of pharmacy. Facilities that register with the FDA as outsourcing facilities under section 503B are primarily overseen and inspected by the FDA on a risk-based schedule, and drugs compounded there are subject to current good manufacturing practice requirements, which drugs from a 503A pharmacy are not.
A 503A pharmacy compounds in response to a prescription for an identified individual patient. That patient-specific prescription is the foundation of the whole arrangement. A licensed provider evaluates you, decides that treatment is appropriate, writes the prescription, and the pharmacy prepares the medication for you on that basis.
Bodi Envi’s prescriptions are dispensed by third party U.S. 503A licensed compounding pharmacies. As Bodi Envi publishes in its own machine readable reference, applicable state boards of pharmacy regulate and inspect 503A compounding pharmacies, and pharmacy operations and sterile compounding practices are subject to applicable U.S. Pharmacopeia standards. VialsRx is the current pharmacy partner for applicable GLP-1 prescriptions, and pharmacy availability may vary by program and patient location.
How it differs from Wegovy® and Ozempic®
The differences are worth stating one at a time, because the shorthand “generic Ozempic®” that people sometimes use is wrong on every count.
Personalized Compounded semaglutide is not a generic. A generic drug is an FDA-approved copy of a brand name drug that the agency has found to be equivalent. No generic semaglutide has been approved. A compounded product has not been through that review at all.
Personalized Compounded semaglutide is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. Wegovy® and Ozempic® went through the full approval process, including the clinical trials described later in this guide.
Personalized Compounded semaglutide is not equivalent to the approved products. Bodi Envi states this directly: compounded personalized semaglutide is not FDA-approved and is not equivalent to FDA-approved products. The formulation, the concentration, the container and the quality controls all differ from the branded product, and no one has run the trials that would show the two behave the same way.
What the two do share is the active ingredient. A provider who prescribes personalized compounded semaglutide is prescribing the same molecule that the branded products contain, prepared in a different way under a different regulatory framework, at a different price. Whether that trade is the right one for you is a clinical judgment, and it is the provider’s to make.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
How it is taken
Semaglutide for weight management is injected subcutaneously, meaning into the fatty tissue just under the skin, once a week. The Wegovy® prescribing information directs patients to inject in the abdomen, thigh or upper arm, to keep to one fixed weekday, and to rotate injection sites with each dose.
Dosing for the approved product follows a schedule of steps. The Wegovy® label sets a recommended starting dose of 0.25 mg once weekly, then increases to 0.5 mg for weeks five through eight, 1 mg for weeks nine through twelve, 1.7 mg for weeks thirteen through sixteen, and a maintenance dose from week seventeen onward, with 1.7 mg and 2.4 mg both listed as maintenance doses for weight reduction in adults. The label explains that the escalation exists to reduce the risk of gastrointestinal side effects, and it allows a provider to delay a step by four weeks if a patient does not tolerate a dose.
With a compounded prescription, that schedule is a reference, not a rule. Your provider sets your starting dose, decides when and whether to increase it, and can hold or lower a dose if you are not tolerating it. Bodi Envi’s pricing does not increase based solely on dosage strength, so the dose decision is a clinical one and not a financial one. Follow your provider’s plan, use the measuring instructions the pharmacy gives you, and ask before changing anything.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the research on semaglutide shows
The headline study for semaglutide in weight management is the STEP 1 trial, published in the New England Journal of Medicine in 2021 by Wilding and colleagues. According to the abstract on PubMed, the trial enrolled 1,961 adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition, who did not have diabetes. They were assigned to 68 weeks of once weekly semaglutide at 2.4 mg or to placebo, both alongside a lifestyle intervention.
The mean change in body weight from baseline to week 68 was 14.9 percent in the semaglutide group compared with 2.4 percent in the placebo group. In the semaglutide group 86.4 percent of participants lost 5 percent or more of their body weight, 69.1 percent lost 10 percent or more, and 50.5 percent lost 15 percent or more. Nausea and diarrhea were the most common adverse events, which the authors describe as typically transient and mild to moderate, and 4.5 percent of the semaglutide group stopped treatment because of gastrointestinal events, compared with 0.8 percent on placebo.
Two caveats belong next to those numbers. First, STEP 1 studied Wegovy®, the branded product at its approved dose, and not a compounded version. No trial of that size has been run on personalized compounded semaglutide, and results from the branded product cannot simply be assumed to carry over. Second, a trial average is not a promise. Some participants lost much more than the average and some lost little. Your own result depends on your dose, how long you stay on treatment, what you eat, how you move and factors nobody can predict in advance. Individual experiences and outcomes vary.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Who may be a candidate
A licensed healthcare provider determines whether treatment is appropriate for each individual patient. That sentence is Bodi Envi’s own published position, and it is the honest answer to the question.
In broad terms, the approved product is indicated for adults with obesity and for adults with overweight who have a weight-related condition, and the trials enrolled people in that range. A provider will also look at what could make treatment unsafe for you. The Wegovy® label lists a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 as a contraindication, along with a known hypersensitivity to semaglutide, and it carries warnings about pancreatitis, gallbladder disease, low blood sugar when combined with certain diabetes medications, kidney injury from dehydration and several other conditions. The safety guide on this site goes through those warnings in detail.
Your assessment asks about all of this so that the provider has what they need. Answer it completely. A provider who does not know about a medication you take or a condition in your family cannot make a safe decision, and the decision is theirs to make.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
How the Bodi Envi program works
Bodi Envi is a LegitScript-certified U.S. telehealth platform that connects eligible adults with licensed healthcare providers for personalized medical weight-management care. It is not a medical practice, pharmacy or medication manufacturer, and it does not compound anything itself.
The program has three parts. You complete an online health assessment from any device. A licensed provider, through Wasef Health, PC for applicable programs, reviews your answers and decides whether personalized compounded semaglutide is appropriate for you. If it is, the prescription goes to VialsRx, the current pharmacy partner for applicable GLP-1 prescriptions, which prepares and ships your medication.
Pricing is published on the Plans page and is the same at every dose. The personalized compounded semaglutide program is $155 per month billed monthly, or $145, $135 and $125 per month on prepaid three, six and twelve month terms. The price includes the assessment, provider review, messaging with your care team, a GLP-1 ebook and diet plan, and the medication when it is prescribed. Medication is included only when a licensed healthcare provider determines treatment is medically appropriate and issues a prescription, and paying for a program does not guarantee one. The cost guide on this site compares these figures with the brand list prices.